1. Home
  2. IDYA vs ARQT Comparison

IDYA vs ARQT Comparison

Compare IDYA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • ARQT
  • Stock Information
  • Founded
  • IDYA 2015
  • ARQT 2016
  • Country
  • IDYA United States
  • ARQT United States
  • Employees
  • IDYA N/A
  • ARQT N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IDYA Health Care
  • ARQT Health Care
  • Exchange
  • IDYA Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • IDYA 1.9B
  • ARQT 1.7B
  • IPO Year
  • IDYA 2019
  • ARQT 2020
  • Fundamental
  • Price
  • IDYA $24.27
  • ARQT $15.01
  • Analyst Decision
  • IDYA Strong Buy
  • ARQT Strong Buy
  • Analyst Count
  • IDYA 13
  • ARQT 6
  • Target Price
  • IDYA $50.82
  • ARQT $18.80
  • AVG Volume (30 Days)
  • IDYA 1.0M
  • ARQT 1.6M
  • Earning Date
  • IDYA 08-05-2025
  • ARQT 08-13-2025
  • Dividend Yield
  • IDYA N/A
  • ARQT N/A
  • EPS Growth
  • IDYA N/A
  • ARQT N/A
  • EPS
  • IDYA N/A
  • ARQT N/A
  • Revenue
  • IDYA $7,000,000.00
  • ARQT $212,819,000.00
  • Revenue This Year
  • IDYA $115.83
  • ARQT $61.01
  • Revenue Next Year
  • IDYA $252.50
  • ARQT $37.95
  • P/E Ratio
  • IDYA N/A
  • ARQT N/A
  • Revenue Growth
  • IDYA N/A
  • ARQT 100.03
  • 52 Week Low
  • IDYA $13.45
  • ARQT $7.86
  • 52 Week High
  • IDYA $44.42
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 63.79
  • ARQT 55.52
  • Support Level
  • IDYA $21.33
  • ARQT $14.10
  • Resistance Level
  • IDYA $25.54
  • ARQT $15.78
  • Average True Range (ATR)
  • IDYA 1.00
  • ARQT 0.74
  • MACD
  • IDYA 0.20
  • ARQT -0.01
  • Stochastic Oscillator
  • IDYA 70.60
  • ARQT 63.55

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: